Swedish diabetes company raises USD 17.5m for phase III trial

Diamyd Medical has raised funding through directed share issues to help construct production facilities and begin phase III study of its diabetes vaccine.

Photo: Diamyd Medical / PR

Among other things, the need for extra funding for a phase III study with Diamyd Medical's diabetes vaccine candidate has made the Swedish company carry out a directed share issue.

The equity issuance, which has raised USD 17.5m (DKK 110m) for the company, targeted several institutional investors as well as qualified private investors in Sweden.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs